Patent ID: 11827912

Abstract:
The present invention relates to chimeric endolysin Lys109 which effectively controls Staphylococcus aureus, wherein the endolysin Lys109 of the present invention has a novel amino acid sequence that has not been conventionally studied. Endolysin Lys109 of the present invention can be used as a biological regulator capable of effectively inhibiting a wide range of Staphylococcus aureus and a biofilm produced thereby. In addition, endolysin Lys109 can kill Staphylococcus aureus without regard for resistance to conventional antibiotics, and thus can be widely used for treatment of diseases caused by Staphylococcus aureus infection. Moreover, endolysin Lys109 can also be used to resolve medical problems caused by Staphylococcus aureus which has antibiotic resistance.